Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the rectum

ABSTRACT: Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the rectum

PROVIDER: PRJNA580485 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in PBMC

Project description:Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) effectively prevents infection with HIV-1. We sought to determine how use of these medications affects gene expression. We performed a small, prospective trial (https://clinicaltrials.gov/ct2/show/NCT02621242) of eight men initiating PrEP with TDF/FTC. We obtained blood before treatment initiation and after two months of daily use. We isolated RNA from cryopreserved peripheral blood mononuclear cells (PBMC). Gene expression was measured from all eight men at both time points.

2020-07-07 | GSE139609 | GEO

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the blood

Project description:Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) effectively prevents infection with HIV-1. We sought to determine how use of these medications affects gene expression. We performed a small, prospective trial (https://clinicaltrials.gov/ct2/show/NCT02621242) of eight men initiating PrEP with TDF/FTC. We obtained blood before treatment initiation and after two months of daily use. We isolated RNA from whole blood (PAXgene tubes). Gene expression was measured from all eight men at both time points.

2020-07-07 | GSE139607 | GEO

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the rectum

Project description:Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) effectively prevents infection with HIV-1. We sought to determine how use of these medications affects gene expression. We performed a small, prospective trial (https://clinicaltrials.gov/ct2/show/NCT02621242) of eight men initiating PrEP with TDF/FTC. We obtained rectal biopsies before treatment initiation and after two months of daily use. We isolated RNA from rectal biopsies preserved with RNAlater. Gene expression was measured from all eight men at both time points.

2020-07-07 | GSE139610 | GEO

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the duodenum

Project description:Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) effectively prevents infection with HIV-1. We sought to determine how use of these medications affects gene expression. We performed a small, prospective trial (https://clinicaltrials.gov/ct2/show/NCT02621242) of eight men initiating PrEP with TDF/FTC. We obtained duodenal biopsies before treatment initiation and after two months of daily use. We isolated RNA from duodenal biopsies preserved with RNAlater. Gene expression was measured from all eight men at both time points.

2020-07-07 | GSE139608 | GEO

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression

Project description:Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression

| PRJNA580482 | ENA

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in PBMC

Project description:Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in PBMC

| PRJNA580486 | ENA

A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Project description:Human immunodeficiency virus (HIV) disproportionately affects men who have sex with men (MSM) and transgender women (TGW). Safe and acceptable topical HIV prevention methods that target the rectum are needed. MTN-017 was a phase 2, 3-period, randomized sequence, open-label, expanded safety and acceptability crossover study comparing rectally applied reduced-glycerin (RG) 1% tenofovir (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF). In each 8-week study period participants were randomized to RG-TFV rectal gel daily, or RG-TFV rectal gel before and after receptive anal intercourse (RAI; or at least twice weekly in the event of no RAI), or daily oral FTC/TDF. MSM and TGW (n = 195) were enrolled from 8 sites in the United States, Thailand, Peru, and South Africa with mean age of 31.1 years (range 18-64). The clinical results were reported here https://www.ncbi.nlm.nih.gov/pubmed/27986684. For the gene expression study, rectal biopsies were obtained from a subset of participants (n = 36) in the United States (Pittsburgh) and Thailand (Bangkok). Biopsies were provided at baseline and after each study period.

2020-07-07 | GSE138723 | GEO

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the duodenum

Project description:Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the duodenum

| PRJNA580487 | ENA

Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the blood

Project description:Effect of pre-exposure prophylaxis with tenofovir disoproxil fumarate and emtricitabine on gene expression in the blood

| PRJNA580488 | ENA

Early termination of a Phase 1 trial of tenofovir disoproxil fumarate intravaginal ring linked to inflammation

Project description:Objective: To assess safety in women of tenofovir disoproxil fumarate (TDF) polyurethane intravaginal ring (IVR) when used continuously for 3 months by healthy, HIV-uninfected, sexually active women, as compared with a placebo intravaginal ring

2020-04-13 | GSE122702 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data